Generate Biomedicines (GENB) vs Palvella Therapeutics (PVLA)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 8, 2026.
Summary
Palvella Therapeutics is the larger company by market cap ($1.89 billion vs $1.80 billion), about 1.1 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | GENB | PVLA |
|---|---|---|
| Share price | $13.99 | $131.34 |
| Market cap | $1.80B | $1.89B |
| 1-day change | +3.10% | +0.57% |
| YTD return | — | +24.76% |
| 1-year return | — | +84.66% |
| 5-year return | — | -63.81% |
| EPS (TTM) | $-2.44 | $-4.85 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| 52-week high | $22.67 | $161.38 |
| 52-week low | $11.00 | $65.93 |
| Distance from 52-week high | -38.29% | -18.61% |
| Analyst consensus | strong_buy | none |
| Avg. price target upside | +92.99% | +75.52% |
| Average volume | 1.04M | 212.38K |
| Shares outstanding | 128.35M | 14.41M |
| Employees | 312 | 29 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
About Generate Biomedicines
GENB stock →Generate Biomedicines, Inc., engaged in the field of generative biology by using machine learning for drug discovery and development through the programming of novel protein therapeutics in the United States. It uses protein-based modalities for drug development.
Health Care · Biotechnology: Pharmaceutical Preparations · 312 employees
About Palvella Therapeutics
PVLA stock →Palvella Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing and commercializing novel therapies to treat patients serious and rare genetic skin diseases. The company's lead product candidate is QTORIN rapamycin, a novel, 3.9% anhydrous topical gel that is in Phase 3 clinical trial for the treatment of microcystic lymphatic malformations, as well as in Phase 2 clinical trial to treat cutaneous venous malformations.
Health Care · Biotechnology: Pharmaceutical Preparations · 29 employees
GENB vs PVLA FAQ
Which is bigger, Generate Biomedicines or Palvella Therapeutics?
Palvella Therapeutics (PVLA) is larger, with a market capitalization of $1.89B compared with $1.80B for Generate Biomedicines (GENB).
Are Generate Biomedicines and Palvella Therapeutics in the same industry?
Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.